A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine

Starting soon · Early Phase 1

Conditions studied: Herpse Zoster

In brief

Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.

Key facts

Study ID

NCT07753265

Run by

Changchun BCHT Biotechnology Co.

People needed

100

Starts

2026-08-13

Expected to finish

2026-09-20

Last updated by the study team

2026-08-07

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age ≥ 50 years old;
• The participant can provide personal informed consent and sign the informed consent form;
• temperature ≤ 37.0℃ on the day of administration;
• capable of complying with the requirements of the clinical trial protocol to complete the trial.

You may not qualify if…

• Subjects with immunodeficiency or immunosuppression caused by underlying diseases or treatments, including primary/acquired immunodeficiency (e.g., AIDS and other virus-induced immunodeficiency), hematologic malignancies (leukemia, lymphoma or other bone marrow/lymphoid neoplasms), ongoing immunosuppressive therapy, or radiotherapy/chemotherapy for malignancies.
• Subjects with a history of allergic reaction to any component of the investigational product.
• Subjects with acute infection or acute exacerbation of chronic infection (vaccination should be deferred).
• Women of non-postmenopausal status with positive pregnancy test, pregnant or lactating women, or those planning pregnancy within 6 months.
• Subjects with prior history of herpes zoster.
• Subjects with prior receipt of varicella or herpes zoster vaccine.
• Receipt of live-attenuated vaccines within 14 days, or subunit/inactivated vaccines within 7 days prior to study vaccination.
• Receipt of whole-blood, plasma or immunoglobulin within 5 months before, or within 3 weeks after study vaccination.
• Receipt of investigational drugs from other clinical trials within 1 month before study vaccination, current participation in another clinical trial, or planned use of investigational agents during study period.
• Current or planned use of salicylates (including aspirin, diflunisal, etc.).
• Uncontrolled abnormal blood pressure at screening (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg despite medication).
• Subjects meeting contraindications or precautions specified in the product's prescribing information.
• Any condition that, in the Investigator's opinion, may interfere with study evaluations.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.